9
Participants
Start Date
May 4, 2011
Primary Completion Date
January 3, 2018
Study Completion Date
January 3, 2018
Sebelipase alfa (SBC-102)
Sebelipase alfa is a recombinant human lysosomal acid lipase enzyme. The investigational medicinal product is an enzyme replacement therapy intended for treatment of participants with LAL Deficiency. Dosing occurred qw for up to 5 years.
Dublin
Cairo
Grenoble
Paris
Irvine
London
Manchester
Lead Sponsor
Alexion Pharmaceuticals, Inc.
INDUSTRY